| Metabolex Inc. Patent applications |
| Patent application number | Title | Published |
|---|
| 20110294836 | ARYL GPR119 AGONISTS AND USES THEREOF - Aryl GPR119 agonists are provided. These compounds are useful for the treatment of diabetic diseases, including Type II diabetes and other diseases associated with poor glycemic control. | 12-01-2011 |
| 20100152295 | METHODS OF REDUCING SMALL, DENSE LDL PARTICLES - The present invention provides methods for increasing LDL particle size. | 06-17-2010 |
| 20100093855 | USE OF (-) (3-TRIHALOMETHYLPHENOXY) (4-HALOPHENYL) ACETIC ACID DERIVATIVES FOR TREATMENT OF INSULIN RESISTANCE, TYPE 2 DIABETES, HYPERLIPIDEMIA AND HYPERURICEMIA - The present invention provides the use of (−)(3-trihalomethylphenoxy)(4-halophenyl)acetic acid derivatives and compositions in the treatment of insulin resistance, Type 2 diabetes, hyperlipidemia and hyperuricemia. | 04-15-2010 |
| 20100093853 | USE OF (-)(3-TRIHALOMETHYLPHENOXY)(4-HALOPHENYL) ACETIC ACID DERIVATIVES FOR TREATMENT OF INSULIN RESISTANCE, TYPE 2 DIABETES AND HYPERLIPIDEMIA - The present invention provides the use of (−)(3-trihalomethylphenoxy)(4-halophenyl)acetic acid derivatives and compositions in the treatment of insulin resistance, Type 2 diabetes and hyperlipidemia. | 04-15-2010 |
| 20100087468 | MODULATORS OF PPAR AND METHODS OF THEIR PREPARATION - The present invention is directed to certain novel compounds represented by Formula (I) and pharmaceutically acceptable salts, solvates, hydrates and prodrugs thereof. The present invention is also directed to methods of making and using such compounds and pharmaceutical compositions containing such compounds to treat or control a number of diseases mediated by PPAR such as glucose metabolism, lipid metabolism and insulin secretion, specifically Type 2 diabetes, hyperinsulinemia, hyperlipidemia, hyperuricemia, hypercholesteremia, atherosclerosis, one or more risk factors for cardiovascular disease, Syndrome X, hypertriglyceridemia, hyperglycemia, obesity and eating disorders. | 04-08-2010 |
| 20090093650 | RESOLUTION OF ALPHA-(PHENOXY)PHENYLACETIC ACID DERIVATIVES WITH NAPHTHYL-ALKYLAMINES - The present invention provides a methods and compounds for producing an enantiomerically enriched α-(phenoxy)phenylacetic acid compound of the formula: | 04-09-2009 |
| 20090054475 | HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS - Compounds and methods are provided for the treatment of, inter alia, Type II diabetes and other diseases associated with poor glycemic control. The compounds of the invention are orally active. | 02-26-2009 |
| 20080318312 | PANCREATIC ISLET TRANSCRIPTION FACTOR AND USES THEREOF - The present invention provides a pancreatic islet transcription factor and methods of treating and diagnosing diabetes. | 12-25-2008 |
| 20080287441 | ALPHA-(TRIFLUOROMETHYL-SUBSTITUTED ARYLOXY, ARYLAMINO, ARYLTHIO OR ARYLMETHYL)-TRIFLUOROMETHYL-SUBSTITUTED PHENYLACETIC ACIDS AND DERIVATIVES AS ANTIDIABETIC AGENTS - Compounds having a formula: | 11-20-2008 |
| 20080248010 | Compositions and methods of using apoptosis signaling kinase related kinase (ASKRK) - The invention provides apoptosis signaling kinase related kinase (ASKRK) nucleic acid and polypeptide sequences and methods of using such sequences to identify modulators of ASKRK. Such modulators can be used for the treatment of diabetes or for delaying the onset of diabetes. The invention also provides methods of diagnosing diabetes or pre-diabetes and methods of making a prognosis based on the detection of ASKRK nucleic acids and proteins. | 10-09-2008 |
| 20080221018 | Crystalline solid and amorphous forms of (-)- halofenate and methods related thereto - The present invention provides crystalline solid and amorphous forms of (−)-halofenate. The crystalline solid forms may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of conditions associated with blood lipid deposition in a mammal, particularly those diseases related to Type 2 diabetes and hyperlipidemia. The invention also relates to a method for preventing or treating Type 2 diabetes and hyperlipidemia in a mammal comprising the step of administering a therapeutically effective amount of crystalline solid and amorphous forms of (−)-halofenate. | 09-11-2008 |
